Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by BioTeckon Jan 10, 2022 1:48pm
232 Views
Post# 34300571

RE:Need PR coverage on Patient- 21 months insulin independent

RE:Need PR coverage on Patient- 21 months insulin independentYou see the problem here? A bunch of investors on a BB are making suggestions for the VP of IR. They keep hiring ibecels who are clueless. They just sit back and get fat off of the DSU. I'm tired of stating what needs to be done because Spill is a class act clown who has his head so far up his rear that he'll (see Charly hiding up there) and likely ruin any opportunities we have. 





steadfast wrote: Just emailed Dr T to remind him to ensure we get coverage on CTV with
Avis Favaro, she is highly respected in the Health field and to ensure
someone contact Gina Kolata, NY Times as we have a much better story
for her than Semma gave her.  We need the IR Team letting the Press know
we have World Class News.  Hopefully, they had the NR's  circulating this morning.

If we can get good Press Coverage and get the stock back up, the Devils
have to cover their shorts.  Time to play hardball with them. 


<< Previous
Bullboard Posts
Next >>